Relacs Health

03/28/2026

Just how "uncommon" are impulse control disorders from dopamine agonists in conditions like restless legs syndrome (RLS)? Andy Berkowski, MD of Relacs Health is quoted in the latest of a series of articles by the BBC's Noel Titheradge related to the devastating effects of these behaviors due to the adverse effects of these drugs on the dopaminergic system.

Warnings for dopamine agonist drugs are to be reviewed after BBC identified an error in patient leaflets.

03/07/2026

It's Daylight Saving Time (DST) tomorrow 😫. Though the tips in this video may be a little too late at this point, we were holding out hope that DST would be abolished by tomorrow. Alas, this video will be useful yet another year!

Unfortunately, Daylight Saving Time (DST) is still with us and Andy Berkowski, MD of ReLACS Health provides five recommendations to help with the Spring Forw...

02/19/2026

For those with restless legs syndrome (RLS) who are on or have been on dopamine agonists like pramipexole or ropinirole, this BBC podcast series will be something to which to listen, as it highlights the under the radar risks of impulse control disorders with these treatments that are no longer recommended as standard treatments for RLS.

Listen to the latest episodes of Shadow World on BBC Audio

02/13/2026

This educational module or "Brick" on restless legs syndrome (RLS) provides an excellent learning opportunity to those practicing medicine, and it can be understandable even to those without a medical background as well. This can be shared with clinicians who are not familiar with the condition as it provides concise, up to date information on RLS.

01/27/2026

Andy Berkowski, MD of Relacs Health appears in this latest Sleep Review article exploring the complexities of the dopamine system in restless legs syndrome (RLS)

If RLS augmentation is caused by an overactive D1 receptor, but a drug such as ecopipam blocks the D1 receptor, then patients could be restored to their baselines, theoretically.

12/23/2025

Andy Berkowski, MD of Relacs Health reviews the major stories from 2025 for the management of restless legs syndrome (RLS), and previews changes to the field for 2026.

2025 was a landmark year for the treatment of restless legs syndrome (RLS). of ReLACS Health reviews the top 5 stories from 2025 heading int...

11/04/2025

A little easier to wake up this morning than in March for Daylight Saving Time? Andy Berkowski, MD of ReLACS Health explains why.

of ReLACS Health describes why turning the clock back in the fall is easier than springing forward. Though sleep expert consensus is in favo...

11/02/2025

This is a well-written AARP article summarizing RLS and highlighting the important updated treatment approach laid out by the American Academy of Sleep Medicine.

​If you have an uncontrollable urge to move your legs at night, you might have RLS. Learn how it develops, who’s at risk and how to ease your symptoms​

11/01/2025

Answer to some of the differences between buprenorphine and tramadol, which are unique opioids in the treatment of RLS.

10/11/2025

This is a well-written personal account of a therapist's experience with her own battle with restless legs syndrome (RLS). (requires Medium account to access)

PART ONE: AN INCURABLE DISEASE

09/19/2025

This year's RLS Foundation Virtual Summit is tomorrow, Saturday 19 at 11 am EDT. Register today! Andy Berkowski, MD of Relacs Health joins other national experts in presenting including a live Q & A to conclude the summit.

Register for our 2025 Virtual Summit! This all-day event explores the latest in technology, treatments, and approaches to managing RLS. Our featured presenters are leading RLS and sleep physicians, researchers and professionals. Attendees can submit questions during each session, to be asked and ans...

09/08/2025

Good news for those suffering with restless legs syndrome (RLS), Noctrix Health, the maker of the Nidra peroneal nerve stimulator device, is ramping up its availability in the US and hopefully internationally. The Nidra is the only device recommended in the 2025 American Academy of Sleep Medicine Clinical Practice Guidelines for the treatment of RLS. Due to dopamine agonist therapy, the previous mainstay of treatment, making RLS significantly worse with long-term use, those with RLS are in desperate need of alternative treatments, particularly non-medication ones like the Nidra.

ACCESS Newswire is the leading global press release distribution service. Tell your story and reach millions of journalists. Contact us today to get started.